Pharmaceutical

GLB-001 by GluBio Therapeutics for Relapsed Acute Myeloid Leukemia: Likelihood of Approval

GLB-001 is under clinical development by GluBio Therapeutics and currently in Phase I for Relapsed Acute Myeloid Leukemia.

Dec 20, 2023 - 18:00
GLB-001 is under clinical development by GluBio Therapeutics and currently in Phase I for Relapsed Acute Myeloid Leukemia.
Read the original article

Tags:

Previous Article

Opinion: Alzheimer’s drug approvals show we need a reevaluation of patient advocacy

Next Article

GLB-001 by GluBio Therapeutics for Refractory Acute Myeloid Leukemia: Likelihood...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: We’re reading about weight loss drugs, a cell therapy for melanoma, and more

STAT+: Pharmalittle: We’re reading about weight loss dr...

Feb 21, 2024

Phase I completion of Sanofi’s vWD therapy demonstrates promise of pipeline

Phase I completion of Sanofi’s vWD therapy demonstrates...

May 16, 2023

MYK-224 by Bristol-Myers Squibb for Diastolic Heart Fai...

Feb 16, 2024